Scarica l'app Stockscreener
31.73
2.04%
-0.66
Dopo l'orario di chiusura:
31.66
-0.07
-0.22%
Precedente Chiudi:
$32.39
Aprire:
$31.83
Volume 24 ore:
17,074
Relative Volume:
0.71
Capitalizzazione di mercato:
$194.19M
Reddito:
-
Utile/perdita netta:
$-7.12M
Rapporto P/E:
-13.80
EPS:
-2.3
Flusso di cassa netto:
$-6.82M
1 W Prestazione:
-10.49%
1M Prestazione:
-24.38%
6M Prestazione:
+40.83%
1 anno Prestazione:
+5,080%
Intervallo 1D:
$28.40
$32.07
Intervallo di 1 settimana:
$28.40
$36.82
Portata 52W:
$0.3438
$54.30
Monopar Therapeutics Inc Stock (MNPR) Company Profile
Nome
Monopar Therapeutics Inc
Settore
Industria
Telefono
(847) 388-0349
Indirizzo
1000 SKOKIE BLVD SUITE 350, WILMETTE
Confronta MNPR con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MNPR
Monopar Therapeutics Inc
|
31.73 | 216.78M | 0 | -7.12M | -6.82M | -2.30 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Monopar Therapeutics Inc Stock (MNPR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-19 | Ripresa | Piper Sandler | Overweight |
| 2025-01-10 | Iniziato | Piper Sandler | Overweight |
| 2024-10-11 | Iniziato | Rodman & Renshaw | Buy |
| 2021-01-28 | Iniziato | ROTH Capital | Buy |
Monopar Therapeutics Inc Borsa (MNPR) Ultime notizie
(MNPR) Trading Advice - news.stocktradersdaily.com
Research Analysts Offer Predictions for MNPR Q2 Earnings - Defense World
Monopar Therapeutics Inc. Announces Closing of $19.2 Million Public Offering of Common Stock - The Globe and Mail
Monopar Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Monopar (MNPR) Projects Financial Stability Through 2026 | MNPR Stock News - GuruFocus
Monopar Therapeutics reports Q1 EPS (38c), consensus (57c) - TipRanks
Monopar Therapeutics Reports First Quarter 2025 Financial Results and Recent Developments - The Manila Times
Monopar Therapeutics SEC 10-Q Report - TradingView
2,037 Shares in Monopar Therapeutics Inc. (NASDAQ:MNPR) Acquired by JPMorgan Chase & Co. - Defense World
(MNPR) Proactive Strategies - news.stocktradersdaily.com
Monopar Therapeutics (MNPR) Showcases ALXN1840's Efficacy for Wi - GuruFocus
Monopar Therapeutics Inc expected to post a loss of 68 cents a shareEarnings Preview - TradingView
Monopar Therapeutics Highlights ALXN1840 Data at EASL 2025 - TipRanks
Monopar Therapeutics (MNPR) Showcases ALXN1840's Efficacy for Wilson Disease | MNPR Stock News - GuruFocus
Monopar Therapeutics (MNPR) Expected to Announce Quarterly Earnings on Thursday - Defense World
Monopar Presents ALXN1840 Late-Breaker Data at EASL 2025 | MNPR Stock News - GuruFocus
Monopar Presents ALXN1840 Late-Breaker Data at EASL 2025 - The Manila Times
Geode Capital Management LLC Acquires 24,530 Shares of Monopar Therapeutics Inc. (NASDAQ:MNPR) - Defense World
Why Monopar Therapeutics Inc. (MNPR) is Surging in 2025 - Insider Monkey
Monopar Announces ALXN1840 Data Selected for Late-Breaker Presentation at EASL Congress 2025 - The Manila Times
Why These 15 Healthcare Stocks Are Surging in 2025 - Insider Monkey
U.S. Severe Oral Mucositis Market Projected To Witness - openPR.com
(MNPR) Investment Analysis - news.stocktradersdaily.com
Monopar Therapeutics Inc. acquired worldwide license to ALXN-18 from Alexion Pharmaceuticals, Inc. for approximately $110 million. - marketscreener.com
(MNPR) Long Term Investment Analysis - news.stocktradersdaily.com
Major Shareholder Sells Big Chunk of Monopar Therapeutics Stock! - TipRanks
Monopar Therapeutics CEO Robinson sells $1.17 million in stock By Investing.com - Investing.com Canada
Jones Trading Reiterates “Hold” Rating for Monopar Therapeutics (NASDAQ:MNPR) - Defense World
HC Wainwright Issues Negative Forecast for MNPR Earnings - Defense World
What is HC Wainwright’s Forecast for MNPR FY2029 Earnings? - Defense World
Monopar Therapeutics downgraded to Hold from Buy at JonesResearch - TipRanks
We Think Monopar Therapeutics (NASDAQ:MNPR) Can Easily Afford To Drive Business Growth - Yahoo
Monopar Therapeutics (NASDAQ:MNPR) Receives “Buy” Rating from HC Wainwright - Defense World
Top 5 Small-cap Biotech Stocks of 2025 - Nasdaq
Monopar Therapeutics Stock Hits 52-Week High at $38.91 - MSN
Monopar Therapeutics Inc: Strategic Advancements and Promising Financial Projections Justify Buy Rating - TipRanks
Buy Rating for Monopar Therapeutics Inc: Strategic Advancements and Promising Financial Outlook - TipRanks
Monopar Therapeutics reports Q4 EPS ($2.23) vs. (60c) last year - TipRanks
Monopar Therapeutics sees cash runway through December 31, 2026 - TipRanks
Monopar Therapeutics Inc. (MNPR) reports earnings - Quartz
Monopar Therapeutics SEC 10-K Report - TradingView
Monopar Secures 2-Year Runway with $60M War Chest, Advances Wilson Disease Drug - Stock Titan
MNPR Stock Price and Chart — NASDAQ:MNPR - TradingView
Here's Why Momentum in Monopar Therapeutics (MNPR) Should Keep going - Yahoo Finance
Piper Sandler Reaffirms “Overweight” Rating for Monopar Therapeutics (NASDAQ:MNPR) - Defense World
Monopar Therapeutics (MNPR) to Release Quarterly Earnings on Thursday - Defense World
Monopar a new overweight at Piper Sandler on rare disease asset - Seeking Alpha
Piper Sandler sets Monopar stock at $76 with Overweight rating - Investing.com
Monopar Therapeutics Inc Azioni (MNPR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.89%
3.74%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):